Abstract

Aim. To assess the efficiency of phosphorothioate antisense oligodeoxynucleotide 1 (S-ODN1) on HCV translation inhibition in PBMC compared to hepatoma cells in vitro for the first time. Materials and Methods. The study included 34 treatment naive HCV patients. IRES domain III and IV sequence variations were tested in 45 clones from 9 HCV patients. PBMC of HCV positive patients were subjected to S-ODN in vitro. Concomitantly HepG2 cells infected by the same patient's serum were also treated with S-ODN1 for 24 and 48 hours. Cellular RNA was tested for HCV plus and minus strands by reverse transcription polymerase chain reaction (RT-PCR). Results. Sequence variations were seen in HCV IRES domain III only while domain IV was conserved among all the tested patient's clones. S-ODN1 successfully inhibited HCV translation in HepG2 cells, while in PBMC inhibition was partial. Conclusion. HCV IRES domain IV is more conserved than domain IIId in genotype 4 HCV patients. S-ODN against HCV IRES domain IV was not efficient to inhibit HCV translation in PBMC under the study conditions. Further studies testing other S-ODN targeting other HCV IRES domains in PBMC should be done.

Highlights

  • Chronic hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [1,2,3]

  • Sera from 9 HCV infected subjects were used in structural analysis of internal ribosome entry site (IRES) domain III, while the rest twenty-five subjects were subjected to HCV detection in serum and peripheral blood mononuclear cells (PBMCs) in order to be further used for comparing S-ODN1 inhibition efficiency in HepG2 versus PBMC in vitro

  • Genotype 4 was the only genotype detected from genotyping of HCV from PBMC positive patients included

Read more

Summary

Introduction

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [1,2,3]. The World Health Organization estimated that 3% of the world’s population or approximately 130–170 million people were chronically infected with HCV at the end of the 20th century, and 2.3–4.7 million new infections occur per year. Hepatitis C virus is responsible for 300 000 deaths annually [4]. HCV mainly is a hepatotropic virus with proven lymphotropism [5,6,7]. These cells represent an extrahepatic reservoir that can be implicated in virus recurrence and persistence [8, 9]. Clearance of HCV RNA in peripheral blood mononuclear cell is a predictor of response to antiviral therapy in patients with chronic hepatitis C [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call